PT  - JOURNAL ARTICLE
AU  - Franz Buchegger
AU  - Cristian Antonescu
AU  - Claudine Helg
AU  - Marek Kosinski
AU  - John O. Prior
AU  - Angelika Bischof Delaloye
AU  - Oliver W. Press
AU  - Nicolas Ketterer
TI  - Six of 12 Relapsed or Refractory Indolent Lymphoma Patients Treated 10 Years Ago with <sup>131</sup>I-Tositumomab Remain in Complete Remission
AID  - 10.2967/jnumed.111.087460
DP  - 2011 Jun 01
TA  - Journal of Nuclear Medicine
PG  - 896--900
VI  - 52
IP  - 6
4099  - http://jnm.snmjournals.org/content/52/6/896.short
4100  - http://jnm.snmjournals.org/content/52/6/896.full
SO  - J Nucl Med2011 Jun 01; 52
AB  - The purpose of our study was to update the safety and efficacy results of radioimmunotherapy in relapsed or resistant indolent or transformed non-Hodgkin lymphoma. Methods: More than 9 y ago, we treated 12 indolent and 4 transformed, relapsed or refractory lymphoma patients with a single administration of nonmyeloablative therapy with tositumomab and 131I-tositumomab. The 16 patients had a mean of 3.1 (range, 1–6) previous chemotherapy and antibody treatments. Results: Six of 12 relapsed indolent lymphoma patients remain disease-free a mean of 9.8 y (range, 8.6–10.7 y) after radioimmunotherapy. Three of 4 transformed lymphoma patients progressed after radioimmunotherapy, and 1 patient had a partial response of 10 mo. Conclusion: Optimal patient benefit might be obtained in indolent lymphoma when administering radioimmunotherapy up-front in combination with chemotherapy and rituximab treatment. However, these results show that radioimmunotherapy alone achieved long-lasting remissions in 6 of 12 (50%) indolent lymphoma patients in relapse after 1 or multiple chemotherapies.